Business Wire

PA-PENNENGINEERING

22.7.2024 09:01:33 CEST | Business Wire | Press release

Share
PennEngineering® Expands Galway, Ireland Facility to Create 70 New Jobs

PennEngineering® a global leader in innovative fastening solutions, has announced the expansion of its operations located in Galway City, Ireland.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722804353/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

This significant extension is set to create 70 new jobs over the next five years, in support of the company's commitment to growth and community development.

The €14 million expansion project, which involves the construction of a new building, includes a state-of-the-art technology and training centre as well as testing laboratories and customer experience centre that will enhance PennEngineering’s capacity to meet the increasing demand for engineering fastening solutions. The new jobs created will span a variety of roles, including manufacturing, engineering, training and more, offering diverse opportunities for local talent.

The expansion project is supported by the Irish Government through IDA Ireland.

Minister of State for Trade Promotion, Digital and Company Regulation, Dara Calleary TD said: “I am pleased to welcome this announcement from PennEngineering which will see the creation of 70 jobs as part of a major expansion project. Investments such as this continue to advance Galway’s position, in particular, as a global hub. I am pleased to welcome this announcement and wish PennEngineering every success.”

“We are thrilled to expand our operations in Galway,” said Mary Ann Fleming, President, PennEngineering Europe. “This investment reflects our confidence in the potential for growth in the region and our commitment to contributing to the local economy. We look forward to welcoming new members to our team and continuing to innovate in the world of fastening technology. Our on-site manufacturing also continues to expand with the introduction of new products, continuing our 82-year history of product innovation in self-clinch fasteners. Supporting training and development of our people and job creation are priorities for us, and this expansion is key to this initiative. As part of this growth announcement, we welcome the board of PennEngineering on site for their biannual meeting and wish them well as they strategise for the future of our global company.”

“Our long-standing partnership with Ireland and the IDA spans over 20 years, and their support has been invaluable in fostering the growth and development of our business in Europe,” according to Pete George, PennEngineering CEO.

The expansion is expected to be completed by January 2025. PennEngineering plans to begin the recruitment process immediately, with job openings to be posted on the company’s website and local job boards.

Mary Buckley, Executive Director of IDA Ireland, said: “PennEngineering has been in Galway since 2001, and this announcement today highlights their ongoing commitment to the West Region. The operation is already a recognised centre of excellence within the global organisation and this 4000m² expansion and 70 jobs further enhances its strategic capabilities in Galway. I wish the PennEngineering team continued success.”

For more information about the expansion and job opportunities, please visit www.pemnet.com/eu/.

About PennEngineering: https://www.penn-eng.com/

Since 1942, PennEngineering® has enjoyed a sustained reputation as the global leader in the fastening industry. The company's brands, PEM®, PROFIL®, Sherex®, PennAuto®, are considered the premier manufacturer for self clinching and other mechanically attached fasteners. Haeger®, for installation systems and Heyco® for molded and stamped products.

PennEngineering’s steadfast commitment to engineering expertise and global innovation ensures that we continue to grow our portfolio with technologies and solutions that allow our customers to not only keep pace with marketplace challenges – but exceed them.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240722804353/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

Seoul Viosys Eyes the $60 Billion AI Data Center Optical Communication Market with Opto Semiconductors27.4.2026 15:00:00 CEST | Press release

Joint Development Talks with Global Optical Communications companiesExpanding Partnerships to Provide Total Transceiver Solution1,800 Patents Secured for High-Performance Optical Communications Seoul Viosys (KOSDAQ: 092190), a company specializing in opto-semiconductor devices, is accelerating its entry into the next-generation photonics market supported by its proprietary “No-wire” and “No-package” fundamental patents—essential technologies for micrometer (μm)-scale miniaturization of opto-semiconductors—as well as its competitiveness in VCSEL technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426926495/en/ Seoul Viosys Optoelectronic Semiconductor Structure Subject to a Permanent U.S. Injunction in February 2026, Covering Similar Products and Employees (Image: Seoul Viosys) As the rapid expansion of AI drives a paradigm shift in data centers from copper-based to optical-based architectures, the company is streng

vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 14:51:00 CEST | Press release

Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye